A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

V. Diéras,Thomas Bachelot,M. Campone,N. Isambert,Florence Joly,Christophe Le Tourneau,Philippe Cassier,Emmanuelle Bompas,Pierre Fumoleau,Sabine Noal,C. Orsini,Marta Jimenez,Diane-Charlotte Imbs,Etienne Chatelut

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

2016

V. Diéras
Thomas Bachelot
M. Campone
N. Isambert
Florence Joly
Christophe Le Tourneau
Philippe Cassier
Emmanuelle Bompas
Pierre Fumoleau
Sabine Noal
C. Orsini
Marta Jimenez
Diane-Charlotte Imbs
Etienne Chatelut

Introduction To determine the feasibility, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT) of pazopanib in combination with cisplatin.

Keywords:

Cisplatin
Aprepitant
Cancer research
Pazopanib
Pharmacology
Medicine
dose escalation
in patient
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations